β-Amyloid (1-40), rat peptide
Not For Human Use, Lab Use Only.
Cat.#: 313821
Price 506.00 USD
-
Product Name
β-Amyloid (1-40), rat peptide
-
Documents
Batch to batch variation of the purity
-
Sequence Shortening
DAEFGHDSGFEVRHQKLVFFAEDVGSNKGAIIGLMVGGVV
-
Sequence
Asp-Ala-Glu-Phe-Gly-His-Asp-Ser-Gly-Phe-Glu-Val-Arg-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val
-
Length (aa)
40
-
Peptide Purity (HPLC)
96.2%
-
Molecular Formula
C190H291N51O57S
-
Molecular Weight
4233.81
-
CAS No.
144409-98-3
-
Source
Synthetic
-
Form
Powder
-
Description
β-Amyloid (1-40), rat is a 40-amino-acid peptide fragment derived from the proteolytic cleavage of the β-amyloid precursor protein (βAPP), a larger transmembrane glycoprotein. The peptide corresponds to the N-terminal portion of the amyloid protein and is one of several fragments (including 1-28 and 1-42) generated from βAPP metabolism. In aqueous solution, the peptide can adopt secondary and tertiary structures over time, and its aggregation state and conformational properties are influenced by factors such as incubation time and temperature.
In experimental hippocampal preparations, deposits of β-Amyloid (1-40) have been shown to produce degeneration of neurons in the CA1 subfield, with affected areas displaying shrunken, dense nuclei, loss of Nissl substance staining, and absence of the dendritic marker MAP2. Apoptotic features, including chromatin condensation and TUNEL-positive profiles, are observed in the CA1 subfield and dentate gyrus in association with the peptide deposits. The peptide deposit is typically localized between the stratum lacunosum moleculare and the granule cell layer, and activated microglia-macrophages are found within and around the deposit, though at lower density than with the 1-42 fragment. These observations indicate that β-Amyloid (1-40) can exert neurotoxic effects on hippocampal neurons under appropriate deposition conditions.
-
Storage Guidelines
Normally, this peptide will be delivered in lyophilized form and should be stored in a freezer at or below -20 °C. For more details, please refer to the manual: Handling and Storage of Synthetic Peptides
-
References
- Miguel-Hidalgo JJ, Cacabelos R. Beta-amyloid(1-40)-induced neurodegeneration in the rat hippocampal neurons of the CA1 subfield. Acta Neuropathol. 1998 May;95(5):455-65. doi: 10.1007/s004010050825. PMID: 9600591.
-
About TFA salt
Trifluoroacetic acid (TFA) is a common counterion from the purification process using High-Performance Liquid Chromatography (HPLC). The presence of TFA can affect the peptide's net weight, appearance, and solubility.
Impact on Net Weight: The TFA salt contributes to the total mass of the product. In most cases, the peptide content constitutes >80% of the total weight, with TFA accounting for the remainder.
Solubility: TFA salts generally enhance the solubility of peptides in aqueous solutions.
In Biological Assays: For most standard in vitro assays, the residual TFA levels do not cause interference. However, for highly sensitive cellular or biochemical studies, please be aware of its presence.
- Molar Concentration Calculator
- Dilution Calculator
- Percent Concentration Calculator
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
Related Products / Services
• Peptide Services: NovoPro's peptide synthesis services include standard chemical peptide synthesis, peptide modification, peptide libraries, and recombinant peptide expression.
• Standard Peptide Synthesis: NovoPro offers quality peptides at the most competitive prices in the industry, starting at $3.20 per amino acid. NovoPro provides PepBox – Automatic Quote Tool for online price calculation.
• Peptide Modifications: NovoPro offers a wide range of peptide modification services including isotope labeling (2H, 15N, and 13C), multiple disulfide bonds, multiple phosphorylations, KLH, BSA, ovalbumin, amidation, acetylation, biotin, FITC, etc.
Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"